Subcutaneous Administrationof Immunoglobulin

Kirmse, Jane

doi:10.1097/00129804-200605001-00002

Cited by 7 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an observational study, 1,500 subcutaneous infusions were clinically followed: none of the patients displayed significant allergic reactions, 5 thus confirming the tolerability of this approach. 20,26 In patients with PID, SCIg was even reported to decrease systemic side effects compared to IVIg or intramuscular administration. 21,32 Further advantages of SCIg include increased patient autonomy and parenteral application without the need for venous access.…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

et al. 2007

View full text Add to dashboard Cite

Intravenous application of immunoglobulins (IVIg) is an effective and usually well tolerated yet costly therapeutic regimen in chronic inflammatory demyelinating polyneuropathy (CIDP). We report two CIDP patients treated with subcutaneous infusion of immunoglobulins (SCIg) after IVIg therapy was shown to be effective. Application of SCIg was well tolerated, easy to manage, and led to stabilization of the disease course. SCIg may represent an effective new therapeutic option in CIDP and is associated with a cost reduction of at least 50% compared to IVIg therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

et al. 2007

View full text Add to dashboard Cite

show abstract

“…SCIG is well tolerated when used in both children and adults, including pregnant women and the elderly population. 592,595,596,[602][603][604][605][606][607][608][609][610][611][612][613][614][615][616] While FDA-approved labeling information carries specific warnings, published clinical evidence demonstrates that SCIG is also well tolerated in patients who have IGA deficiency. 53,55,603,617 Providers should be aware that systemic adverse reactions have been reported in patients receiving SCIG therapy: While most reactions have been mild, 55,595,598,603,618 severe reactions rarely occur.…”

Section: Routementioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

526

462

View full text Add to dashboard Cite

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

show abstract

“…Nowadays, subcutaneous immunoglobulin (SCIG) infusions are used as an alternative to intravenous immunoglobulin (IVIG) administration in adults and children with primary or secondary antibody deficiencies [6,7]. SCIG infusions were shown to be efficacious, safe, and well tolerated [8].…”

Section: Introductionmentioning

confidence: 99%

Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency

et al. 2010

View full text Add to dashboard Cite

Background Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy. Methods We evaluated the efficacy and safety of the SCIG Vivaglobin ® (formerly known as Beriglobin ® SC) under real-life conditions in a post-marketing observational study in 82 patients with primary or secondary antibody deficiencies. Health-related quality of life (HRQoL) was evaluated in a subset of 30 patients previously treated with IVIG (including 11 children < 14 years) using the Short Form 36 (SF-36) for patients ≥ 14 years of age (adults) and the Child Health Questionnaire - Parental Form 50 (CHQ-PF50) for children < 14 years of age. Treatment preferences were assessed in adults. Results The mean serum immunoglobulin G (IgG) trough level during SCIG treatment (7.5 g/L) was higher than during previous IVIG treatment (6.6 g/L; p < 0.01). The investigators assessed the efficacy of SCIG therapy as "excellent" in 89% of patients. No systemic adverse drug reactions were observed. Improvements by ≥ 5 points were observed in 5 of 8 SF36 subscales and in 6 of 12 CHQ-PF50 subscales. Statistically significant improvements (p ≤ 0.05) were observed for the SF-36 subscales of bodily pain, general health perceptions, and vitality (adults), and for the CHQ-PF50 subscales of general health perceptions, parental impact - time, parental impact - emotional, and family activities (children). Patients preferred SCIG over IVIG therapy (92%) and home therapy over therapy at the clinic/physician (83%). Conclusion This study confirms that therapy with Vivaglobin ® at home is effective, safe, well tolerated, and improves quality of life in patients with antibody deficiency.

show abstract

Subcutaneous Administrationof Immunoglobulin

Cited by 7 publications

References 13 publications

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy

Update on the use of immunoglobulin in human disease: A review of evidence

Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency

Contact Info

Product

Resources

About